Novo stock surges on rival’s weak sales data
Novo Nordisk shares rose 5.4 percent on Friday following sales data from competitor Eli Lilly. Data reveals that Eli Lilly’s weight-loss pill, Foundayo, recorded 3,707 prescriptions in its second week, while Novo Nordisk’s oral version of Wegovy saw 18,410 prescriptions in the same period. Senior analyst Søren Løntoft Hansen notes that Eli Lilly’s launch has […]